GlycoMimetics, Inc. (NASDAQ: GLYC), a biopharmaceutical company focused on discovering and developing novel small-molecule drug candidates to treat rare diseases, announced today that the Japan Patent Office (JPO) has issued Patent No. 6366150, for uproleselan (GMI-1271). The newly issued patent covers uproleselan’s composition of matter as well as pharmaceutical formulations, and expires in December 2032.
{iframe}https://www.businesswire.com/news/home/20180814005038/en/GlycoMimetics-Receives-Japanese-Patent-Uproleselan-GMI-1271{/iframe}